Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | QDPR | P09417 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309415 | 1.00 | NAMPT (0.52) | NAMPTQDPRKDM4EMAPTTHRB | |
| SCHEMBL22608983 | 0.93 | PDE4B (0.59) | NAMPTQDPRKDM4EMAPTTHRB | |
| SCHEMBL30493305 | 0.90 | NAMPT (0.52) | NAMPTQDPRKDM4EMAPTTHRB | |
| SCHEMBL20347002 | 0.90 | NAMPT (0.52) | NAMPTQDPRKDM4EMAPTTHRB | |
| SCHEMBL19702757 | 0.90 | DPP4 (0.55) | NAMPTKDM4EMAPTTHRBDPP4 | |
| SCHEMBL15650585 | 0.87 | PDE4B (0.53) | MAPTDPP4PDE4BHRH3TRPV3 | |
| SCHEMBL3988015 | 0.86 | DPP4 (0.52) | NAMPTKDM4EMAPTTHRBDPP4 | |
| SCHEMBL4846419 | 0.86 | MAPT (0.51) | NAMPTKDM4EMAPTTHRBDPP4 | |
| SCHEMBL23858326 | 0.86 | NAMPT (0.53) | NAMPTQDPRKDM4EMAPTTHRB | |
| SCHEMBL30075838 | 0.86 | NAMPT (0.53) | NAMPTQDPRKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-4225748-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | NAMPT 1836/4885QDPR 1331/4885KDM4E 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.